Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Multicenter, Open-label Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma

NCT00719472 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00719472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00719472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Multicenter, Open-label Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma
Lead sponsor
Genentech, Inc.
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2008
Completion date
May 31, 2011
Enrollment
451 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin's lymphoma